Biotech

Lilly licenses AlzeCure Alzheimer’s asset for $1B biobucks

Lilly has signed a heavily backloaded agreement to license a gamma-secretase modulator treatment for Alzheimer's disease for up to $1 billion biobucks.

Will Maddox Jun 9, 2026 10:16am

Bial bails after Parkinson’s fail, axing asset over phase 2 miss

Jun 9, 2026 5:22am

How AI is reshaping biopharma decision-making

Brought to you by Clarivate

graphic of a larger shark chomping up a smaller one

GSK inks $10.6B Nuvalent buyout to challenge Roche and Pfizer

Jun 9, 2026 4:41am

Managing complexity across biopharma modalities

Brought to you by SK Pharmteco

City lays foundation for RNAi renaissance with nearly $100M

Jun 8, 2026 4:00pm